<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1096</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10468556</PubmedId>
            <Abstract>An important component of triple-drug anti-AIDS therapy is 2', 3'-dideoxy-3'-thiacytidine (3TC, lamivudine). Single mutations at residue 184 of the reverse transcriptase (RT) in HIV cause high-level resistance to 3TC and contribute to the failure of anti-AIDS combination therapy. We have determined crystal structures of the 3TC-resistant mutant HIV-1 RT (M184I) in both the presence and absence of a DNA/DNA template-primer. In the absence of a DNA substrate, the wild-type and mutant structures are very similar. However, comparison of crystal structures of M184I mutant and wild-type HIV-1 RT with and without DNA reveals repositioning of the template-primer in the M184I/DNA binary complex and other smaller changes in residues in the dNTP-binding site. On the basis of these structural results, we developed a model that explains the ability of the 3TC-resistant mutant M184I to incorporate dNTPs but not the nucleotide analog 3TCTP. In this model, steric hindrance is expected for NRTIs with beta- or L- ring configurations, as with the enantiomer of 3TC that is used in therapy. Steric conflict between the oxathiolane ring of 3TCTP and the side chain of beta-branched amino acids (Val, Ile, Thr) at position 184 perturbs inhibitor binding, leading to a reduction in incorporation of the analog. The model can also explain the 3TC resistance of analogous hepatitis B polymerase mutants. Repositioning of the template-primer as observed in the binary complex (M184I/DNA) may also occur in the catalytic ternary complex (M184I/DNA/3TCTP) and contribute to 3TC resistance by interfering with the formation of a catalytically competent closed complex.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>10027-32</ArticlePages>
            <ArticleTitle>Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Sarafianos</LastName>
                    <ForeName>S G</ForeName>
                </Author>
                <Author>
                    <LastName>Das</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Clark</LastName>
                    <ForeName>A D</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Boyer</LastName>
                    <ForeName>P L</ForeName>
                </Author>
                <Author>
                    <LastName>Hughes</LastName>
                    <ForeName>S H</ForeName>
                </Author>
                <Author>
                    <LastName>Arnold</LastName>
                    <ForeName>E</ForeName>
                </Author>
            </Authors>
            <Affiliations>Center for Advanced Biotechnology and Medicine (CABM) and Rutgers University Chemistry Department, 679 Hoes Lane, Piscataway, NJ 08854-5638, USA.</Affiliations>
            <ArticleChemicalList>Macromolecular Substances;RNA, Viral;Lamivudine;HIV Reverse Transcriptase</ArticleChemicalList>
            <ArticleMeshHeadingsList>Allosteric Regulation; Amino Acid Sequence; Amino Acid Substitution; Conserved Sequence; Dimerization; Drug Resistance, Microbial; HIV Reverse Transcriptase(chemistry; genetics; metabolism); HIV-1(drug effects; enzymology; genetics); Humans; Lamivudine(chemistry; pharmacology); Macromolecular Substances; Models, Molecular; Molecular Sequence Data; Nucleic Acid Conformation; Point Mutation; Protein Conformation; RNA, Viral(chemistry; metabolism); Templates, Genetic</ArticleMeshHeadingsList>
            <Journal>
                <Volume>96</Volume>
                <Issue>18</Issue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <Issn>0027-8424</Issn>
                <MedlineTa>Proc Natl Acad Sci U S A</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Epitope of Fab28 on HIV-1 RT</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>R199, K223, E224, P225, P226, F227, W229, M230, G231</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>NP_789739.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11676</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>PDB 1C9R</LocationOfData>
                <EpitopeId>164095</EpitopeId>
                <ReferenceRegion>R199, K223, E224, P225, P226, F227, W229, M230, G231</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope residues are calculated from the structure [PDB: 1C9R] as the antigen residues at 4 Ã… distance from the antibody.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1 and PDB 1J5O</LocationOfData>
                        <BCellId>1910999</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>NP_789739.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11676</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HIV-1 RT (66 kDa isoform)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 doses at a 2-wk interval and 1 dose 4 days before cell fusion</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was originally described in the reference: Ferris et al. (1990) Virology 175(2): 456-464 [PMID: 1691562]. Mice were immunized with purified RT (66 kDa form).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.5</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Fab 28 on the HIV-1 RT p51 subunit was determined from the crystal structure of Fab 28 bound to the complex of HIV-1 RT p51/p66 dimer/dsDNA (19-mer/18-mer). Fab 28 binds to the p51 palm subdomain and has no contacts with either the p66 subunit or the dsDNA. The HIV-1 RT p66 subunit contained the M184I mutation in the polymerase active site. Both RT subunits contained the C280S mutation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>28</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>28</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>2HMI_D</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>2HMI_C</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>HIV-1 RT p51/p66 (M184I) dimer/dsDNA</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>NP_789739.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11676</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                    <SourceMolecule>
                                        <GenBankId>YP_001856242.1</GenBankId>
                                    </SourceMolecule>
                                    <MoleculeSourceOrganismId>11676</MoleculeSourceOrganismId>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1J5O</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>B</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <CuratedContacts>
                                <EpitopeResidues>B: ;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: ; L: ;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>B: R199, K223, E224, P225, P226, F227, W229, M230, G231</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: S32, W54, R60, I102, T103, S104, V105, T106, D107, S108; L: Y32, Y91, S92, F94, W96</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>581.7</ContactAreaForAntigen>
                                <ContactAreaForAntibody>533.2</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

